Substituted pyridine spleen tyrosine kinase (SYK) inhibitors

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Merck Sharp & Dohme Corp., , Merck Canada Inc. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp., , Merck Canada Inc.’s patent US 9376418 B2 deals with Substituted pyridine spleen tyrosine kinase (SYK) inhibitors.
invention provides certain substituted Pyridines of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, P3, R4, rcy, CY, and t as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.